Loading…
FHTX
Foghorn Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 344174107
$6.00-3.54%Price as of Aug 29, 18:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $356.31M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.96
- ROE
- —
- Profit margin
- -175.78%
- Revenue growth
- +112.70%
- Beta
- 2.83
- 52-week high
- $7.61
- 52-week low
- $3.27
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -72.4% over 5Y.
today you would have $251.26▼ -74.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $5.40 | $4.72 | $6.45 | $6.38 | $22.87 | $20.27 | |
| P/S | 12.7x | 10.3x | 11.6x | 8.0x | 13.9x | 718.2x | 1735.5x |
| P/B | 9.8x | — | — | — | 2381.3x | 9.8x | 5.1x |
| EPS | -$1.18 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OCGNOcugen, Inc. | $1.04 | — | — | — | — | $352.67M |
| PALIPalisade Bio Inc | $2.00 | 3.2x | 2.9x | — | -51.37% | $348.54M |
| ENTAEnanta Pharmaceuticals Inc | $11.95 | — | 3.4x | — | -70.12% | $348.05M |
| UPBUpstream Bio, Inc. | $6.69 |
About the company
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- 106
- Watertown, United States
Company description provided by Yahoo Finance.